Immunai
Mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
€909m (Public information from Oct 2021)
New York City New York (HQ), Tel Aviv-Yafo Tel Aviv District (founding location)
Authorizing premium user...